drugset / Trial / NCT00005867

Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

NCT00005867 ↗

Phase 3 Completed 310 enrolled Lymphoma Trials Office
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two regimens of combination chemotherapy and comparing how well they work in treating patients with aggressive non-Hodgkin's lymphoma.

Timeline

Start
1998-01
Primary completion
—
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown — Intravenous
Subject Cyclophosphamide Other / unclassified — Intravenous
Subject Doxorubicin Other / unclassified — Intravenous
Subject Etoposide Small molecule — Intravenous
Subject Mitoxantrone Small molecule — Intravenous
Subject Prednisolone Other / unclassified — Oral
Subject Vincristine Small molecule — Intravenous

Indications